Tempus AI annual ebitda
2022
2023
2024
2025
Tempus AI EBITDA Growth & History (TEM)
Tempus AI's calculated EBITDA was −$220.8M for fiscal 2025.
View full Tempus AI company overviewTempus AI annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$220.8M | $443.9M | — |
| 2024 | 2024-12-31 | −$664.7M | −$490.2M | — |
| 2023 | 2023-12-31 | −$174.5M | $73.8M | — |
| 2022 | 2022-12-31 | −$248.4M | — | — |
Tempus AI quarterly ebitda
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$68.8M | −$15.4M | — |
| Q1 2026 | 2026-03-31 | −$77.3M | −$16.5M | — |
| Q4 2025 | 2025-12-31 | −$53.7M | −$9.9M | — |
| Q3 2025 | 2025-09-30 | −$52.9M | −$6.0M | — |
| Q2 2025 | 2025-06-30 | −$53.4M | $473.6M | — |
| Q1 2025 | 2025-03-31 | −$60.8M | −$13.8M | — |
| Q4 2024 | 2024-12-31 | −$43.8M | — | — |
| Q3 2024 | 2024-09-30 | −$46.8M | −$7.5M | — |
| Q2 2024 | 2024-06-30 | −$527.1M | −$487.1M | — |
| Q1 2024 | 2024-03-31 | −$47.0M | — | — |
| Q3 2023 | 2023-09-30 | −$39.3M | — | — |
| Q2 2023 | 2023-06-30 | −$39.9M | — | — |
Tempus AI ebitda trends
Between the periods ended 2022-12-31 and 2025-12-31, Tempus AI's ebitda increased from −$248.4M to −$220.8M, a change of $27.5M. The latest reported quarter, Q2 2026, shows −$68.8M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Tempus AI source filings ↗Community posts
Tempus plans disease-focused dataset covering 100,000 whole genomes
Tempus AI ($TEM) launched an initiative to build a research platform linking 100,000 whole-genome sequences with long-term clinical information over several years. The company intends to focus on disease populations and treatment outcomes, ...